Ofirmev
PreclinicalSmall molecule
Ofirmev is one of 14 small molecule programs targeting Cleft Palate. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Cleft Palate
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Chirocaine
PPurdue Pharma LP
Phase 3
TISSEEL
UUniversity Hospital, Ghent
Approved
Methadone Hydrochloride
NNational Institute of Allergy and Infectious Diseases (NIAID)
Approved
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Marcaine
IInnocoll
Phase 2
Paracetamol
GSKPhase 2
Fentanyl/hydromorphone
DDuke University
Approved
Unasyn
SStanford University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hip Arthroplasty1 trial
Post-surgical1 trial
Efficacy Study of IV Ibuprofen vs IV Acetaminophen Post Surgical Extraction
Unknown status·—·Phase 2·NCT02133326·67 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ofirmev. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLoma Linda University